12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok
12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok
12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
i det nordamerikanske register, af størrelsesorden 80-90% inden<strong>for</strong> en søgetid på ca. tre<br />
måneder.<br />
Hvis der ikke kan lokaliseres matchende familie eller ubeslægtet (herunder NS-donor) donor<br />
inden <strong>for</strong> ca. tre måneder må muligheden <strong>for</strong> protokolleret haplotransplantation overvejes.<br />
Referencer<br />
K Schmiegelow, E Forestier, M Hellebostad, M Heyman, J Kristinsson, S Söderhäll and M Taskinen On behalf of<br />
the Nordic Society of Paediatric Haematology and Oncology (NOPHO). Long-term results of NOPHO ALL-92<br />
and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 24: 345-354 2010.<br />
Pulsipher MA, Bader P, Klingebiel T, Cooper LJ. Allogeneic transplantation <strong>for</strong> pediatric acute lymphoblastic<br />
leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel<br />
chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow<br />
Transplant. 2009 Jan;15(1 Suppl):62-71. Review.<br />
NOPHO – ALL 2008 Final protocol version 1e Treatment Protocol <strong>for</strong> Children (1.0 - 17.9 years of age) and<br />
young adults. (18-45 years of age) with Acute Lymphoblastic Leukemia. NOPHO hjemmeside.<br />
EsPhALL: Amendment proposal An open-label study to evaluate the safety and efficacy of IMATINIB with<br />
chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL). January 2010.<br />
NOPHO hjemmeside.<br />
IntReALL 2010. International Study <strong>for</strong> Treatment of Childhood Relapsed ALL. A Randomised Phase III Study of<br />
the International BFM Study Group Conducted by the Resitstant Disease Committee. Extended Synopsis<br />
Version 22.01.2010.<br />
Bailey LC, Lange BJ, Rheingold SR, Bunin NJ. Bone-marrow relapse in paediatric acute lymphoblastic<br />
leukaemia. Lancet Oncol. 2008 Sep;9(9):873-83. Review.<br />
INTERFANT-06 International Collaborative Treatment Protocol <strong>for</strong> Infants Under One Year with Acute<br />
Lymphoblastic or Biphenotypic leukaemia. NOPHO Hjemmeside.<br />
Zweidler-McKay PA, Hilden JM. The ABCs of infant leukemia. Curr Probl Pediatr Adolesc Health Care. 2008<br />
Mar;38(3):78-94. Review.<br />
Lausen,B.F.; Heilmann,C.; Vindeløv,L.; Jacobsen,N. Outcome of acute lymphoblastic leukemia in Danish<br />
children after allogeneic bone marrow transplantation. Superior survival following transplantation with matched<br />
unrelated donor garfts. Bone Marrow Transplant. 22, 325-330 (1998).<br />
Saarinen-Pihkala UM, Gustafsson G, Carlsen N, Flaegstad T, Forestier E, Glomstein A, Kristinsson J, Lanning<br />
M, Schroeder H, Mellander L; Nordic Society of Pediatric Hematology and Oncology. Outcome of children with<br />
high-risk acute lymphoblastic leukemia (HR-ALL): Nordic results on an intensive regimen with restricted central<br />
nervous system irradiation. Pediatr Blood Cancer. 2004 Jan;42(1):8-23.<br />
Saarinen-Pihkala UM, Gustafsson G, Ringdén O, Heilmann C, Glomstein A, Lönnerholm G, Abrahamsson J,<br />
Bekassy AN, Schroeder H, Mellander L; Nordic Society of Pediatric Hematology and Oncology. No disadvantage<br />
in outcome of using matched unrelated donors as compared with matched sibling donors <strong>for</strong> bone marrow<br />
transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol. 2001 Jul<br />
15;19(14):3406-14.<br />
25
Change language